Editas Medicine Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of common stock from Editas Medicine at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The company's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading on Wednesday, February 3, 2016 under the ticker symbol "EDIT."

Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering.Cowen and Company is acting as lead manager, and JMP Securities is acting as co-manager for the offering.

A registration statement relating to the securities being sold in this offering has been filed with and declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; orJ.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,Edgewood, NY 11717, or by telephone at (866) 803-9204.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Editas Medicine 
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Media Contact 
Dan Budwick
Pure Communications, Inc.
(973) 271-6085 

Investor Contact
Jesse Baumgartner
Stern Investor Relations, Inc.
(212) 362-1200